Topics:

Zeneca Acquires US Rights to Kadian, an Oral Morphine Product

Zeneca Acquires US Rights to Kadian, an Oral Morphine Product

WILMINGTON, Del--Zeneca Inc. has reached an agreement with Faulding Services Inc. (Adelaide, South Australia) for exclusive US rights to purchase, distribute, and promote Faulding's sustained-release morphine sulfate product Kadian, an oral medication taken once or twice daily.

A new drug application (NDA) for use of Kadian in the treatment of moderate to severe chronic pain is currently under FDA review. The product is approved and available in Australia and several European countries.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.